ADVERSE EVENTS

The safety of LIXIANA® has been evaluated in two Phase 3 studies including 21,105 patients with NVAF (ENGAGE AF-TIMI 48) and 8,292 patients with VTE (Hokusai-VTE) with an average exposure to LIXIANA® 60 mg/30 mg of 2.5 years and 251 days, respectively.

Reference (click to access full publication)